申请人:Gilead Connecticut, Inc.
公开号:US08247550B2
公开(公告)日:2012-08-21
Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
本文描述了化学式I的化合物,其具有抑制Btk的作用。本文还描述了包含至少一种化学式I化合物的制药组合物,以及至少一种从载体、佐剂和赋形剂中选择的药用可接受载体。本文还描述了治疗对Btk活性和/或B细胞活性抑制有响应的某些疾病的患者的方法。本文还描述了检测样品中Btk存在的方法。